[go: up one dir, main page]

WO2001069260A3 - A lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer - Google Patents

A lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer Download PDF

Info

Publication number
WO2001069260A3
WO2001069260A3 PCT/US2001/007393 US0107393W WO0169260A3 WO 2001069260 A3 WO2001069260 A3 WO 2001069260A3 US 0107393 W US0107393 W US 0107393W WO 0169260 A3 WO0169260 A3 WO 0169260A3
Authority
WO
WIPO (PCT)
Prior art keywords
cln2p
breast cancer
breast
activity
primary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/007393
Other languages
French (fr)
Other versions
WO2001069260A2 (en
Inventor
Raju K Pullarkat
Mohammad A Junaid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation for Mental Hygiene Inc
Original Assignee
Research Foundation for Mental Hygiene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation for Mental Hygiene Inc filed Critical Research Foundation for Mental Hygiene Inc
Priority to JP2001568088A priority Critical patent/JP2003527607A/en
Priority to AU2001247317A priority patent/AU2001247317A1/en
Priority to CA002403373A priority patent/CA2403373A1/en
Priority to US10/221,565 priority patent/US20030211554A1/en
Priority to EP01920239A priority patent/EP1269193A2/en
Publication of WO2001069260A2 publication Critical patent/WO2001069260A2/en
Publication of WO2001069260A3 publication Critical patent/WO2001069260A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

The present invention describes diagnostic and prognostic assays to detect in vascular and tissue samples the presence and activity of the lysosomal pepstatin-insensitive proteinase, CLN2p, which has been newly found to be associated with breast cancer and serves as a novel biomarker for breast cancer, including primary, non-primary, or metastatic breast tumors, neoplasms and carcinomas. The activity of CLN2p was discovered to be significantly elevated when measured in breast tissue samples from patients with primary breast carcinoma, compared with CLN2p levels in normal sample controls, thereby demonstrating an approximately two- to seventeen-fold higher CLN2p activity in breast tumors. These higher levels of CLN2p activity in breast tumors were positively correlated with several known breast cancer biomarkers, such as cathepsin D, estrogen receptor and progesterone receptor. The present invention thus provides CLN2p as new biomarker for use in the detection, diagnosis and prognosis of breast cancer.
PCT/US2001/007393 2000-03-13 2001-03-08 A lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer Ceased WO2001069260A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001568088A JP2003527607A (en) 2000-03-13 2001-03-08 Lysosomal pepstatin-insensitive proteolytic enzyme as a novel biomarker for breast cancer detection and diagnosis
AU2001247317A AU2001247317A1 (en) 2000-03-13 2001-03-08 A lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer
CA002403373A CA2403373A1 (en) 2000-03-13 2001-03-08 A lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer
US10/221,565 US20030211554A1 (en) 2001-03-08 2001-03-08 Lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer
EP01920239A EP1269193A2 (en) 2000-03-13 2001-03-08 A lysosomal pepstatin-insensitive proteinase as biomarker for breast cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18886100P 2000-03-13 2000-03-13
US60/188,861 2000-03-13

Publications (2)

Publication Number Publication Date
WO2001069260A2 WO2001069260A2 (en) 2001-09-20
WO2001069260A3 true WO2001069260A3 (en) 2002-05-10

Family

ID=22694851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/007393 Ceased WO2001069260A2 (en) 2000-03-13 2001-03-08 A lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer

Country Status (5)

Country Link
EP (1) EP1269193A2 (en)
JP (1) JP2003527607A (en)
AU (1) AU2001247317A1 (en)
CA (1) CA2403373A1 (en)
WO (1) WO2001069260A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089073A2 (en) * 2003-04-03 2004-10-21 Genpath Pharmaceuticals, Incorporated Inducible breast cancer model
WO2007088971A1 (en) * 2006-02-03 2007-08-09 Messengerscape Co., Ltd. Gene group applicable to cancer prognostication
CA2644343A1 (en) * 2006-03-17 2007-09-27 Biomarin Pharmaceutical Inc. Assays for detection of antibodies to lysosomal enzymes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024065A1 (en) * 1995-02-03 1996-08-08 Oncogene Science, Inc. Methods for the detection of pro-cathepsins and uses thereof
WO1998055872A1 (en) * 1997-06-03 1998-12-10 Amdl, Inc. Immunoassay for the detection of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024065A1 (en) * 1995-02-03 1996-08-08 Oncogene Science, Inc. Methods for the detection of pro-cathepsins and uses thereof
WO1998055872A1 (en) * 1997-06-03 1998-12-10 Amdl, Inc. Immunoassay for the detection of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUNAID M A ET AL: "A lysosomal pepstatin-insensitive proteinase as anovel biomarker for breast carcinoma", THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, vol. 15, no. 2, 2000, pages 129 - 134, XP008001480 *

Also Published As

Publication number Publication date
AU2001247317A1 (en) 2001-09-24
WO2001069260A2 (en) 2001-09-20
CA2403373A1 (en) 2001-09-20
EP1269193A2 (en) 2003-01-02
JP2003527607A (en) 2003-09-16

Similar Documents

Publication Publication Date Title
Yang et al. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer
Leygo et al. DNA methylation as a noninvasive epigenetic biomarker for the detection of cancer
Urakami et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection
Sanguedolce et al. Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: literature review
Leja et al. Early detection of gastric cancer beyond endoscopy-new methods
WO2006089212A3 (en) Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
EP1804062A3 (en) YKL-40 as a marker and prognostic indicator for cancers
Yamamoto et al. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less
WO2002035232A3 (en) Method for detecting ovarian cancer based on human kallikrein 6 (hk6)
CA2384579A1 (en) Early cancer tumor marker
WO2002037112A3 (en) Detection of ovarian cancer
Adams et al. Promoter methylation in cytology specimens as an early detection marker for esophageal squamous dysplasia and early esophageal squamous cell carcinoma
Zaorsky et al. The dilemma of a rising prostate-specific antigen level after local therapy: what are our options?
Mueller et al. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients
Hung et al. Evaluating the prediction of breast cancer survival using lymph node ratio
Lin et al. Aberrant promoter methylation of PCDH17 (Protocadherin 17) in serum and its clinical significance in renal cell carcinoma
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2002064015A8 (en) Pin1 as a marker for prostate cancer
Lamb et al. Prostate cancer: the new evidence base for diagnosis and treatment
WO2001069260A3 (en) A lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer
WO2012145399A2 (en) Methods of diagnosing cancer in a patient
Botelho et al. Does baseline total testosterone improve the yielding of prostate cancer screening?
Bangma et al. Free and total prostate‐specific antigen in a screened population
Pappas et al. Early detection and staging of adenocarcinoma of the pancreas
Scarlett et al. Classification of pancreatic cystic lesions using SELDI‐TOF mass spectrometry

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 568088

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001247317

Country of ref document: AU

Ref document number: 2403373

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001920239

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001920239

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10221565

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001920239

Country of ref document: EP